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alone: 3, other combination chemotherapy: 9 and 1 underwent re-
duced intensity allogeneic transplantation. Two pts were not fit to
receive further treatment and had rapidly progressive disease
(PD). Of the treated pts, 6 achieved CR (4 subsequently pro-
gressed), 5 PR and 7 had PD. Eleven pts remain alive (only 2 in
CR) with PD accounting for all deaths. With a median follow-up
of 31 months (m) post relapse for living pts, median PFS from the
time of relapse post-ASCT was 5 m and OS was 34 m. No signifi-
cant predictors of PFS could be identified. For OS, univariate anal-
ysis identified time to relapse (TTR; p5 0.011), performance status
(PS; p5 0.010) and total IPI score (p5 0.041) as being statistically
significant. Only TTR remained significant on the multivariate
model. TTR less than 12 months portends a very poor outcome
(2 year OS 0% compared to 62% form TTR .12 m; p\ 0.001).
Conclusion: Pts with MCL who relapse after ASCT do poorly, es-
pecially those relapsing within one year of ASCT. New therapeutic
approaches incorporating maintenance therapy post-ASCT or the
use of novel agents such as bortezomib or mTOR inhibitors should
be explored in this group.
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FLUID RELATED COMPLICATIONS WITH FILGRASTIM (G-CSF) 10 MCG/
KG ONCE DAILY VERSUS 5 MCG/KG TWICE DAILY IN AMYLOIDOSIS PA-
TIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL MOBILIZATION
Perreault, S.K.1, Burzynski, J.A.1, Hoskin, T.L.2, Leung, N.3,
Buadi, F.K.3, Dispenzieri, A.3, Hayman, S.R.3, Kumar, S.K.3,
Lacy, M.Q.3, Gertz, M.A.3, Wolf, R.C.1 1Mayo Clinic, Rochester,
MN; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN.
Background:High dosemelphalan followed by peripheral blood
stem cell (PBSC) transplantation is an established therapy for AL
amyloidosis. One limitation is the frequent fluid related complica-
tions that occur during PBSC mobilization (Blood 2004:1143a).
The development of fluid related complications during mobiliza-
tion predicts decreased survival after PBSC transplant (Blood
2005;106:3353). At Mayo Clinic, G-CSF 10 mcg/kg once daily
was the standard until 2004. In attempt to reduce fluid related com-
plications the practice changed to G-CSF 5 mcg/kg twice daily in
July 2004. It is unknown if this change impacted the incidence of
fluid related complications during PBSC mobilization. Methods:
We conducted a retrospective evaluation of patients with amyloid-
osis undergoing PBSCmobilization at Mayo Clinic. Following IRB
approval, patients were identified by reviewing theMayoClinic dys-
proteinemia data base and data extracted from the medical record.
Forty-six patients from the once daily and 22 patients from the twice
daily were excluded due to use of mobilization agents in addition to
G-CSF, second mobilization, syngeneic transplant or consent re-
fusal. A fluid related complication was defined as new peripheral
edema, pleural effusion or ascites, or initiation of supportive therapy
(diuretics, albumin, or dopamine) to promote diuresis. Results:
From 7/98 to 8/03, 123 patients received once daily G-CSF.
From 7/04 to 8/07, 182 patients received twice daily G-CSF. Organ
involvement was similar in both series; single organ (43% vs 36%; p
5 0.2), two organs (38% vs 62%; p 5 0.5) and 3 or more organs
(22% vs 26%; p5 0.5).Most patients had either kidney involvement
(65% vs 71%; p5 0.2) or heart involvement (51% vs 57%; p5 0.3).
Baseline edema (61% vs 53% (p 5 0.06)) and baseline diuretic use
(58% vs 55% (p 5 0.7)) was similar in both groups. Fluid related
complications occurred with similar frequency regardless of admin-
istration schedule, 50% vs 51% (p5 0.9). Two patients in the once
daily and 4 patients in the twice daily administration died prior to
PBSC transplant. In patients that received a PBSC transplant, sur-
vival was similar at day 100; 88% vs 92% and one year; 83% vs 88%
(p 5 0.6). Conclusion: Changing from once daily to twice daily
G-CSF administration in patients with amyloidosis did not impact
the incidence of fluid related complications or mortality at day 100
or one year after PBSC transplant.
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PHASE II TRIAL EVALUATING APREPITANT (AP) FOR PREVENTION OF
NAUSEA AND VOMITING SECONDARY TO HIGH-DOSE CYCLOPHOSPHA-
MIDE (CY) ADMINISTERED TO PATIENTS UNDERGOING AUTOLOGOUS
(A) PERIPHERAL BLOOD PROGENITOR CELL (PBPC) MOBILIZATION
Abidi, M.H.1,2, Abrams, J.1,2, Ibrahim, R.3, Ayash, L.1,2, Cronin, S.3,
Al-Khadimi, Z.1,2, Lum, L.1,2, Ratanatharathorne, V.1,2, Uberti, J.1,2
1Wayne State University, Detroit, MI; 2Barbara Ann Karmanos Cancer
Center, Detroit,MI; 3Eugene AppelbaumCollege of Pharmacy and Allied
Health Professions, Detroit, MI.
Background:Adequate PBPCmobilization in the range of 2–5
106 CD341 cells/kg body weight is a prerequisite for administration
of high-dose chemotherapy and A-PBPC transplant. Cy and filgras-
tim combination provides a better PBPC yield as compared to fil-
grastim, which has a failure rate of 15–20%. In this setting, high-
dose Cy is associated with significant nausea and vomiting. Ap is
a new antiemetic that is a Neurokinin-1 receptor antagonist and
may reduce the incidence of this side effect. We have conducted
a phase II trial evaluating efficacy and safety of adding Ap to stan-
dard antiemetic combination of 5-HT3 antagonists and adjusted
dose of corticosteroids. Primary objective of this study was the con-
trol of acute vomiting without the use of rescue medications at 24
hours post Cy. The data of the first interim report are presented.
Methods: From May 2005 to May 2007, 22 pts were enrolled,
four of whom are not evaluable for response. Three pts did not re-
ceive Ap; one withdrew consent after a single dose. All received Cy 4
gm/m2 and filgrastim (10–16 mcg/kg/d) for stem cell mobilization.
Granisetron 1 mg, dexamethasone 10 mg and Ap 125 mg was ad-
ministered orally 1 hour before Cy followed by Ap 80 mg once daily
 2 days. This study used Simon’s optimal two-stage design con-
strained to fewer than 40 pts with 10% type I error and 85% statis-
tical power. Ap is considered effective if it prevents nausea and
vomiting in at least 65% of patients. Ap is judged ineffective if the
rate of vomiting control was 45% or less. Results: Ten (55%) of
18 response-evaluable pts had no vomiting episodes and received
no rescue medications during the first 24 hours following Cy. Of
those who did not achieve the primary endpoint, four pts reported
no vomiting episodes but received rescue medications. The other
four pts had at least one vomiting episode and one received rescue
anti-emetic. Ten pts had no delayed vomiting (25–120 hrs). Ten
pts reported no nausea in 24 hours and five pts experienced mild
nausea. Only 6/18 (33%) pts experienced moderate to severe de-
layed nausea (25–120 hrs). No toxicities related to Ap were noted
for any patients. All pts had adequatemobilization of stem cells (me-
dian CD341: 7.57  106/kg) and proceeded to A-PBPC transplant.
Conclusion: The results of this interim analysis justify continua-
tion to stage 2 with enrollment of 17more patients. Ap has potential
to effectively control nausea and emesis in pts receiving high-dose
Cy.
Comparison of Complications based on G-CSF Schedule of
Administration
Once
daily
Filgrastim
n 5 123 N (%)
Twice
daily
Filgrastim
n 5 182 N (%) p value
Fluid Complications 63 (50) 93 (51) 0.9
Hospitalization 28 (23) 24 (13) 0.03
Hospitalization related
to fluid complication
21 (17) 10 (5) 0.001
Diuretic adjustment
needed
42 (34) 89 (49) 0.012
Non-pharmacological
intervention*
10 (8) 9 (5)
Death prior to PBSC
Transplant
2 (1.6) 4 (2.2)
Patient did not undergo
PBSC transplant
9 (7.3) 37 (20)
*Thoracentesis, Paracentesis, Hemodialysis, Pleurodesis, and Me-
chanical Ventilation.
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TOTAL BODY IRRADIATION BASED (TBI) VERSUS CHEMOTHERAPY-
BASED-PREPARATIVE REGIMENS BEFORE AUTOLOGOUS STEM CELL
TRANSPLANTS FOR NON-HODGKIN’S LYMPHOMA
Liu, H.1, Seftel, M.2, Demers, A.3, Schroeder, G.1, Nugent, Z.3,
Butler, J.1, Rubinger, M.2 1CancerCare Manitoba, University of Mani-
toba, Winnipeg, MB, Canada; 2CancerCare Manitoba, University of
Manitoba, Winnipeg, MB, Canada; 3CancerCare Manitoba, Winnipeg,
MB, Canada.
Objectives: The optimum high dose preparative regimen for
non-Hodgkin lymphoma (NHL) patients undergoing autologous
stem cell transplantation (ASCT) is unknown.We compared the ra-
diation-based regimen of cyclophosphamide, etoposide and 12 Gy
total body irradiation (CY/E/TBI) to carmustine, etoposide, cytar-
abine and melphalan (BEAM) in NHL patients who received
ASCT. We investigated acute and long-term toxicities, disease
free survival (DFS), overall survival (OS) of these two regimens.
Methods: Historical cohort study was performed at a provincial
cancer centre. Cause specific survival was determined with the Ka-
plan-Meier method. Suvival between groups was compared using
the log-rank test.Results:FromMar-1991 to Sep-2005, 79 patients
received CY/E/TBI (n5 32) or BEAM (n5 47). Histology was in-
dolent in 30 and aggressive in 49 patients. Cell source was bone
marrow in six and 73 received peripheral blood progenitor cells.
Prior to ASCT, ten patients were in complete remission, 47 had
chemo-sensitive disease and 22 had chemo-resistant disease. There
were only two cases of interstitial pneumonitis, with one in each
preparative regimen group. There were six transplant related
deaths; two in the BEAM group and four were in TBI group. The
TBI based group has a higher mean mucosits score (p 5 0.03).
Five year DFS was 47% and 51% in the TBI and BEAMgroups, re-
spectively (p 5 0.41). Five year OS was 50% and 64% for the TBI
and BEAM based groups (p5 0.07). Multivariate analyses revealed
that patients with more advanced disease status and raised LDH at
ASCT independently predicted inferiorDFS. There was one case of
acute myeloid leukemia and two of prostate cancer, all of whom
were in the TBI group. Conclusions: As compared to a BEAM
based regimen, a 12 Gy TBI-based regimen resulted in a similar
DFS. The TBI group had a trend toward poorer OS than
a BEAM-based regimen that may accounted for by other confound-
ing variables. There did not appear to be excess pulmonary or other
acute toxicities in the TBI based group. Randomized controlled tri-
als are required in order to establish the superiority of either
regimen.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT): A SINGLE CEN-
TER EXPERIENCE IN COLOMBIA
Abello, V., Rosales, C., Pedraza, E., Esguerra, H.J., Rosales, M.L.,
Linares, A. Clınica de Marly, Bogota, Colombia.
Here we report the results of autologous and allogenic SCT in
a single institution in Bogota, Colombia, between 1993 and 2007.
We performed 532 SCT in 526 patients, 227 allogenic and 305
autologous.
In 294 (96.4%) of autologous-SCT, stem cells were obtained
from peripheral blood.Mean 2.97 106/kg (0.31–30) CD341 cells,
in 3 (1–8) apheresis, were collected. 224 (73.7%) were movilized us-
ing Cyclofosfamide plus G-SCF. The rest were movilized with var-
ious chemotherapy regimens or G-CSF alone. Indications for auto-
SCT were: Non-Hodgkins Lymphoma 115, Hodgkin disease 93,
multiple myeloma 59, solid tumors 18, acute leukemias 17, other
3. Mean age was 40.1 years (5–68). 189 (61.9%) were male. Most
common conditioning regimens for lymphomas were BEAM and
BEM. All MM patients were conditioned with Melphalan 200
mg/m2. Hospitalization median time was 27 days (14–87). Day
100 TRM (transplant related mortality) was 6.23%. At mean
31.23 months (0.16–161) follow up overall and relapse free survival
are 71% and 66.4% respectively. 60% of deaths were related to dis-
ease relapse.
Of 227 allo-SCT, in 214 SC were obtained from peripheral
blood, only 13 were obtained from bone marrow. 153 (59%) were
males. Most common indications for transplant were: Chronic
myeloid leukemia 57, acute myeloid leukemia 46, acute lymphoid
leukemia 41, bone marrow failure syndromes 44, Hodgkin’s and
non-Hodgkin lymphomas 14, MDS 9, other 12. Mean age was
30.1 (4–63) years. 72% of patients and 76% of donors were IgG
CMV positive. Most common conditioning regimens for acute
leukemias and lymphomas were BuCy, BuCy-etoposide, busulfan-
fludarabine; and for aplastic anemia high dose cyclofosfamide or cy-
clophosphamide plus ATG. Hospitalization median time was 34
days (17–103). Day 100 TRM was 16.7%. At mean 25.72 months
(0.27–147) follow up, overall and relapse free survival are 53.2%
and 50.9% respectively.
Results described here are similar of ones reported in other cen-
ters around de world, they confirm that SCT is feasible in centers of
developing world.
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PITUITARY APOPLEXY COMPLICATING AUTOLOGOUS STEM CELL
TRANSPLANTATION
Ling Cheng, K., Devoe, C., John, V., Kiner, B., Cannon, M.,
Gissinger, D., Klocke, J., Bayer, R.-L. North Shore University Hospital,
Manhasset, NY.
Pituitary Apoplexy (PA) is an uncommon neurologic event that
results from sudden hemorrhage or infarction of the pituitary gland.
Most of these events occur in patients with undiagnosed pituitary
adenoma. There are various precipitating causes. We report
a case of PA precipitated by thrombocytopenia during autologous
stem cell transplantation.
The patient is a 48M with history of stage II multiple myeloma
initially treated with lenalidomide and dexamethasone. The patient
then proceeded to Auto PSCT. His preparative regimen consisted
of melphalan 200 mg/m2. Initial lab values showed a platelet count
of 429K/ul. The patient became febrile on Day 4 and was started on
broad spectrum antibiotics. Voriconazole replaced fluconazole
when fevers persisted. On Day 7, the patient complained of blurry
vision. This was the first day plts were below 10K/ul. A possible cul-
prit was voriconazole and it was discontinued. The patient com-
plained his peripheral vision was particularly compromised, and
bitemporal hemianopsia was confirmed. CT of the brain revealed
a 2.3 2.5 cmhemorrhagic pituitarymass. Platelets were transfused
to keep plts above 75K/ul. Hydrocortisone was begun, as was des-
mopressin, for developing diabetes insipidus.MRI confirmed a large
suprasellar mass consisitent with a pituitary macroadenoma that
contained hemorrhage. The incidence of PA with pituitary ade-
noma is variable, but has been reported to be as high as 27.7%.
Many patients have nonfunctional adenomas or are asymptomatic
prior to the event. Clinical symptoms of PA are also variable but
the most common symptoms include headache, nausea, and visual
deficits. As in most cases, our patient had an undiagnosed pituitary
adenoma and was asymptomatic. The thrombocytopenia and im-
munocomprimise of PSCT can make the pituitary vulnerable to
hemorrhage and abscess, both reported causes of apoplexy.
Patients Characteristics (N 5 18)
Sex: Male/Female 10/8
Median Age (years) 50 (range: 32–62)
Race
Caucasians 15
African Americans 3
Diagnosis
APL 1
HD 1
NHL 8
MM 8
Median CD341 Cells/kg 7.57 million
(range: 2.93–76.16)
APL: Acute Promyelocytic Leukemia, HD: Hodgkin Disease,
MM: Multiple Myeloma, NHL: Non-Hodgkin Lymphoma.
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